In addition, quercetin was suggested to be used as a novel therapeutic option for NAFLD due to its prebiotic capacity, which could improve gut dysbiosis by inhibiting endotoxemia-mediated TLR4/NF-κB signaling pathway activation, suppressing the subsequent inflammation and induced reticulum stress, and blocking the deregulation of lipid metabolism gene expression [16]. The gene discussed is TLR4; the disease is metabolic dysfunction-associated steatotic liver disease.